Bayer

Bayer
source
Name	Bayer AG
Type	Public (Aktiengesellschaft)
Traded as	FWB: BAYN, DAX component
Foundation	01 August 1863 in Barmen
Founder	Friedrich Bayer and Johann Friedrich Weskott
Location	Leverkusen, North Rhine-Westphalia, Germany
Key people	Werner Baumann (Chairman), Bill Anderson (CEO)
Industry	Pharmaceuticals, Life Sciences
Products	Pharmaceuticals, crop science, consumer health products
Revenue	€47.637 billion (2023)
Num employees	101,369 (2023)

Bayer is a German multinational pharmaceutical and biotechnology company, and one of the largest in the world. Founded in the 19th century, it has grown into a global enterprise with core competencies in the life science fields of health care and agriculture. The company is headquartered in Leverkusen and is a constituent of the DAX stock market index, with its shares traded on the Frankfurt Stock Exchange. Bayer's long history is marked by significant scientific innovations, a vast portfolio of well-known products, and a series of major corporate acquisitions and legal controversies.

History

The company was founded on 1 August 1863 in Barmen by dye salesman Friedrich Bayer and master dyer Johann Friedrich Weskott. Initially named "Friedr. Bayer et comp.", it produced and sold synthetic dyes, benefiting from the rapid growth of the German chemical industry during the late 19th century. A pivotal moment came in 1897 when chemist Felix Hoffmann, working at the company's facilities in Elberfeld, first synthesized acetylsalicylic acid in a stable form, which was later marketed under the trademark Aspirin. In 1904, the company was transformed into a joint-stock company, Farbenfabriken vorm. Friedr. Bayer & Co. The early 20th century saw expansion, including the construction of a major new plant in Leverkusen, which later became the global headquarters. During World War I, the company was part of the IG Farben conglomerate, a relationship that continued until the conglomerate's dissolution after World War II. The post-war era focused on rebuilding and expanding its pharmaceutical and chemical divisions, leading to the development of groundbreaking products like the antibiotic Ciprofloxacin and the Yasmin series of oral contraceptives. The 21st century has been defined by transformative acquisitions, most notably the $63 billion purchase of Monsanto in 2018, which made it the world's largest seed and pesticide company.

Business segments

Bayer operates through three primary divisions. The Pharmaceuticals division, one of the largest globally, focuses on research, development, and marketing of prescription products, with key therapeutic areas including cardiology, women's healthcare, and oncology. Notable products from this segment include the anticoagulant Xarelto and the cancer treatments Nubeqa and Vitrakvi. The Crop Science division, bolstered by the Monsanto acquisition, is a leader in seeds, herbicides, and pesticides, providing solutions for modern agriculture; its portfolio includes Roundup herbicides and a wide array of genetically modified seeds. The Consumer Health division markets a broad range of over-the-counter medications, nutritional supplements, and dermatological products, with globally recognized brands such as Aleve, Claritin, Coppertone, and Dr. Scholl's.

Products

The company's product portfolio spans from historic inventions to modern blockbuster drugs. Its most famous product is Aspirin, originally launched in 1899, which remains one of the world's best-known pain relievers. In prescription pharmaceuticals, Xarelto (rivaroxaban) is a leading anticoagulant used to prevent stroke and venous thromboembolism. The Crop Science division's flagship product is the glyphosate-based herbicide Roundup, alongside a vast library of genetically modified seeds for crops like soybeans, corn, and cotton. The Consumer Health division sells analgesic Aleve (naproxen), the allergy medication Claritin (loratadine), the antifungal Lotrimin, and the sunscreen brand Coppertone.

Corporate affairs

Bayer is governed by a two-tier board system, with a Management Board led by the CEO and a Supervisory Board representing shareholders and employees. Its stock is a blue-chip component of Germany's DAX index. Major institutional shareholders include BlackRock and Capital Group Companies. The company maintains significant research and development facilities worldwide, including major sites in Berlin, Cambridge, Massachusetts, and Monheim. Its corporate strategy has been heavily influenced by large-scale mergers and acquisitions, such as the purchases of Schering AG in 2006 and Monsanto in 2018. Bayer is a founding member of the European Chemical Industry Council and actively engages with industry groups like PhRMA and CropLife International.

Controversies

The company has been involved in numerous significant legal and ethical controversies. Its historical involvement with the IG Farben conglomerate, which used forced labor from concentration camps during World War II, remains a dark chapter. In modern times, its acquisition of Monsanto brought immense liability related to Roundup; thousands of lawsuits alleged the herbicide's key ingredient, glyphosate, causes non-Hodgkin lymphoma. By 2024, Bayer had settled tens of thousands of these claims for over $15 billion. Another major litigation involves PCBs (polychlorinated biphenyls), for which it faces claims related to environmental contamination. The pharmaceutical division has faced issues, including thousands of lawsuits over alleged side effects of its Yasmin birth control pills and the cholesterol-lowering drug Trasylol. These controversies have significantly impacted the company's finances, reputation, and market valuation, leading to major management restructuring and ongoing strategic reviews.

Category:Pharmaceutical companies of Germany Category:Companies listed on the Frankfurt Stock Exchange Category:Agrochemical companies Category:DAX